New antibody drug treatments for lymphoma

Bibliography

• Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med 1982;306:517-22
   PubMed Web of Science ®Google Scholar
• Maloney DG, Brown S, Czerwinski DK, Monoclonal anti-idiotype antibody therapy of B-cell lymphoma: the addition of a short course of chemotherapy does not interfere with the antitumor effect nor prevent the emergence of idiotype-negative variant cells. Blood 1992;80:1502-10
   PubMed Web of Science ®Google Scholar
• Reff ME, Carner K, Chambers KS, Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45
   PubMed Web of Science ®Google Scholar
• McLaughlin P, Grillo-Lopez AJ, Link BK, Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Belch A, CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005;105:1417-23
   PubMed Web of Science ®Google Scholar
• Marcus R, Imrie K, Solal-Celigny P, Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma. J Clin Oncol 2008;26:4579-86
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Kneba M, Dreyling M, Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32
   PubMed Web of Science ®Google Scholar
• Herold M, Haas A, Srock S, Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol 2007;25:1986-92
   PubMed Web of Science ®Google Scholar
• Salles G, Mounier N, de Guibert S, Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study. Blood 2008;112:4824-31
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Grillo-Lopez AJ, White CA, Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999;17:268-76
   PubMed Web of Science ®Google Scholar
• Vose JM, Link BK, Grossbard ML, Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001;19:389-97
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117-26
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trumper L, Osterborg A, CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91
   PubMed Web of Science ®Google Scholar
• Schulz H, Bohlius JF, Trelle S, Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-14
   PubMed Web of Science ®Google Scholar
• Sacchi S, Pozzi S, Marcheselli L, Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients. Cancer 2007;109:2077-82
   PubMed Web of Science ®Google Scholar
• van Oers MH, Klasa R, Marcus RE, Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301
   PubMed Web of Science ®Google Scholar
• Hochster H, Weller E, Gascoyne RD, Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized Phase III ECOG1496 Study. J Clin Oncol 2009;27:1607-14
   PubMed Web of Science ®Google Scholar
• Salles GA, Seymour JF, Feugier P, Rituximab maintenance for 2 years in patients with untreated high tumor burden follicular lymphoma after response to immunochemotherapy. J Clin Oncol 2010;28(15 Suppl):8004
   Google Scholar
• Vidal L, Gafter-Gvili A, Leibovici L, Rituximab maintenance for the treatment of patients with follicular lymphoma: systematic review and meta-analysis of randomized trials. J Natl Cancer Inst 2009;101:248-55
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004;104:3064-71
   PubMed Web of Science ®Google Scholar
• Buske C, Hoster E, Dreyling M, The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia 2009;23:153-61
   PubMed Web of Science ®Google Scholar
• Hallek M, Fingerle-Rowson G, Fink A-M, First-line treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) improves overall survival (OS) in previously untreated patients (pts) with advanced chronic lymphocytic leukemia (CLL): results of a randomized phase III trial on behalf of an International Group of Investigators and the German CLL Study Group. ASH Annual Meeting Abstracts. Blood 2009;114:535
   PubMed Web of Science ®Google Scholar
• Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007;44:3823-37
   PubMed Web of Science ®Google Scholar
• Bello C, Sotomayor EM. Monoclonal antibodies for B-cell lymphomas: rituximab and beyond. Hematology Am Soc Hematol Educ Program 2007:233-42
   PubMedGoogle Scholar
• Cragg MS, Morgan SM, Chan HTC, Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003;101:1045-52
   PubMed Web of Science ®Google Scholar
• Chan HTC, Hughes D, French RR, CD20-induced lymphoma cell death is independent of both caspases and its redistribution into Triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480-9
   PubMed Web of Science ®Google Scholar
• Ivanov A, Beers SA, Walshe CA, Monoclonal antibodies directed to CD20 and HLA-DR can elicit homotypic adhesion followed by lysosome-mediated cell death in human lymphoma and leukemia cells. J Clin Invest 2009;119:2143-59
   PubMed Web of Science ®Google Scholar
• Ivanov A, Krysov S, Cragg MS, Illidge T. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res 2008;14:4925-34
   PubMed Web of Science ®Google Scholar
• Beers SA, Chan CHT, James S, Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. Blood 2008;112:4170-7
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Xiu Y, Komura K, Antibody isotype-specific engagement of Fcgamma receptors regulates B lymphocyte depletion during CD20 immunotherapy. J Exp Med 2006;203:743-53
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000;6:443-6
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Xiu Y, Poe JC, Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. Blood 2008;112:1205-13
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8
   PubMed Web of Science ®Google Scholar
• Shibata-Koyama M, Iida S, Misaka H, Nonfucosylated rituximab potentiates human neutrophil phagocytosis through its high binding for FcgammaRIIIb and MHC class II expression on the phagocytotic neutrophils. Exp Hematol 2009;37:309-21
   PubMed Web of Science ®Google Scholar
• Selenko N, Maidic O, Draxier S, CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells. Leukemia 2001;15:1619-26
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Hyrien O, Mosmann TR, Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab. Blood 2009;113:3809-12
   PubMed Web of Science ®Google Scholar
• Cartron G, Dacheux L, Salles G, Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002;99:754-8
   PubMed Web of Science ®Google Scholar
• Weng WK, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003;21:3940-7
   PubMed Web of Science ®Google Scholar
• Beers SA, French RR, Chan HT, Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection. Blood 2010;115:5191-201
   PubMed Web of Science ®Google Scholar
• Wang SY, Veeramani S, Racila E, Depletion of the C3 component of complement enhances the ability of rituximab-coated target cells to activate human NK cells and improves the efficacy of monoclonal antibody therapy in an in vivo model. Blood 2009;114:5322-30
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Grillo-Lopez AJ, Baars JW, Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-11
   PubMed Web of Science ®Google Scholar
• Chan HT, Hughes D, French RR, CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer Res 2003;63:5480-9
   PubMed Web of Science ®Google Scholar
• Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood 2004;103:2738-43
   PubMed Web of Science ®Google Scholar
• Teeling JL, Mackus WJ, Wiegman LJ, The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006;177:362-71
   PubMed Web of Science ®Google Scholar
• Pawluczkowycz AW, Beurskens FJ, Beum PV, Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX. J Immunol 2009;183:749-58
   PubMed Web of Science ®Google Scholar
• Teeling JL, French RR, Cragg MS, Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood 2004;104:1793-800
   PubMed Web of Science ®Google Scholar
• Cillessen SAGM, Mackus WJM, Castricum KCM, Chemotherapy-refractory diffuse large B-cell lymphomas (DLBCL) are effectively killed by ofatumumab-induced complement-mediated cytoxicity. ASH Annual Meeting Abstracts. Blood 2007;110(11):2346
   Google Scholar
• Bleeker WK, Munk ME, Mackus WJ, Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br J Haematol 2008;140:303-12
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Gadeberg O, Johnson P, First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood 2008;111:5486-95
   PubMed Web of Science ®Google Scholar
• Hagenbeek A, Fayad L, Delwail V, Evaluation of ofatumumab, a novel human CD20 monoclonal antibody, as single agent therapy in rituximab-refractory follicular lymphoma. ASH Annual Meeting Abstracts. Blood 2009;114(22):935
   Google Scholar
• GlaxoSmithKline. Single agent ofatumumab vs. single agent rituximab in follicular lymphoma relapsed after rituximab-containing therapy. ClinicalTrials.gov NCT01200589. Available from: http://clinicaltrials.gov/ct2/show/NCT01200589?term=NCT01200589&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• GlaxoSmithKline. Ofatumumab and bendamustine combination therapy compared with bendamustine monotherapy in indolent B-cell non-Hodgkin's lymphoma (NHL) unresponsive to rituximab or a rituximab-containing regimen (COMPLEMENT A+B). ClinicalTrials.gov NCT01077518. Available from: http://clinicaltrials.gov/ct2/show/NCT01077518?term=NCT01077518&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• GlaxoSmithKline. Ofatumumab (Humax-CD20) with CHOP in FL patients (MUNIN). ClinicalTrials.gov NCT00494780. Available from: http://clinicaltrials.gov/ct2/show/NCT00494780?term=NCT00494780&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• GlaxoSmithKline. Phase II study of ofatumumab plus ICE or DHAP chemotherapy regimen in relapsed/ refractory DLBCL. ClinicalTrials.gov NCT00823719. Available from: http://clinicaltrials.gov/ct2/show/NCT00823719?term=NCT00823719&rank=1[Last accessed 11 February 2011]
   Google Scholar
• GlaxoSmithKline. Ofatumumab in patients with relapsed/progressive diffused large B-cell lymphoma (DLBCL) ineligible for or relapse/progression after transplant. ClinicalTrials.gov NCT00622388. Available from: http://clinicaltrials.gov/ct2/show/NCT00622388?term=NCT00622388&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• GlaxoSmithKline. A Phase II trial of ofatumumab in subjects with waldenstrom's macroglobulinemia. ClinicalTrials.gov NCT00811733. Available from: http://clinicaltrials.gov/ct2/show/NCT00811733?term=NCT00811733&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Goldenberg DM, Rossi EA, Stein R, Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood 2009;113:1062-70
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Chen S, Characterization of a new humanized anti-CD20 monoclonal antibody, IMMU-106, and its use in combination with the humanized anti-CD22 antibody, epratuzumab, for the therapy of non-Hodgkin's lymphoma. Clin Cancer Res 2004;10:2868-78
   PubMed Web of Science ®Google Scholar
• Goldenberg DM, Chang C, Rossi EA, Session 14 – biological treatments: activity of veltuzumab, a second-generation humanized anti-cd20 mAb, in laboratory and clinical studies. Ann Oncol 2008;19(Suppl 4): iv129-iv130
   Google Scholar
• Morschhauser F, Leonard JP, Fayad L, Humanized anti-CD20 antibody, veltuzumab, in refractory/recurrent non-Hodgkin's lymphoma: phase I/II results. J Clin Oncol 2009;27:3346-53
   PubMed Web of Science ®Google Scholar
• Wegener W. Phase I/II study of subcutaneously administered veltuzumab (hA20) in NHL and CLL. ClinicalTrials.gov NCT00546793. Available from: http://clinicaltrials.gov/ct2/show/NCT00546793?term=NCT00546793&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Vugmeyster Y, Beyer J, Howell K, Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother 2005;28:212-19
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Marlton P, Vitolo U, Interim results of a Phase I/II study of ocrelizumab, a new humanised anti-CD20 antibody in patients with relapsed/refractory follicular non-Hodgkin's lymphoma. ASH Annual Meeting Abstracts. Blood 2007;110(11):645
   Google Scholar
• Bowles JA, Wang SY, Link BK, Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006;108:2648-54
   PubMed Web of Science ®Google Scholar
• Applied Molecular Evolution. Safety and efficacy study of an anti-CD20 monoclonal antibody (AME-133v) to treat non-Hodgkin's lymphoma. ClinicalTrials.gov NCT00354926. Available from: http://clinicaltrials.gov/ct2/show/NCT00354926?term=NCT00354926&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Umana P, Moessner E, Bruenker P, Novel 3rd generation humanized type II CD20 antibody with glycoengineered Fc and modified elbow hinge for enhanced ADCC and superior apoptosis induction. ASH Annual Meeting Abstracts. Blood 2006;108(11):229
   Google Scholar
• Umana P, Ekkehard M, Peter B, GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, exhibits superior anti-tumor efficacy and superior tissue B cell depletion in vivo. ASH Annual Meeting Abstracts. Blood 2007;110(11):2348
   Google Scholar
• Dalle S, Reslan L, Manquat SB, Compared antitumor activity of GA101 and rituximab against the human RL follicular lymphoma xenografts in SCID Beige mice. ASH Annual Meeting Abstracts. Blood 2008;112(11):1585
   Google Scholar
• Friess T, Gerdes C, Nopora A, GA101, a novel humanized type II CD20 antibody with glycoengineered Fc and enhanced cell death induction, mediates superior efficacy in a variety of NHL xenograft models in comparison to rituximab. ASH Annual Meeting Abstracts. Blood 2007;110(11):2338
   Google Scholar
• Salles G, Morschhauser F, Lamy T, Phase I study of RO5072759 (GA101) in patients with relapsed/refractory CD20+ non-Hodgkin lymphoma (NHL). ASH Annual Meeting Abstracts. Blood 2009;114(22):1704
   Google Scholar
• Sehn LH, Assouline SE, Stewart DA, A Phase I study of GA101 (RO5072759) monotherapy followed by maintenance in patients with multiply relapsed/refractory CD20+ malignant disease. ASH Annual Meeting Abstracts. Blood 2009;114(22):934
   PubMedGoogle Scholar
• Fine G. A study to investigate the efficacy and safety of bendamustine compared with bendamustine+RO5072759 (GA101) in patients with rituximab-refractory, indolent non-Hodgkin's lymphoma (GADOLIN), ClinicalTrials.gov NCT01059630. Available from: http://clinicaltrials.gov/ct2/show/NCT01059630?term=NCT01059630&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Park SI, Press OW. Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol 2007;14:632-8
   PubMed Web of Science ®Google Scholar
• Knox SJ, Goris ML, Trisler K, Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70
   PubMed Web of Science ®Google Scholar
• Buchsbaum DJ, Wahl RL, Glenn SD, Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 1992;52:637-42
   PubMed Web of Science ®Google Scholar
• Kapadia NS, Engles JM, Wahl RL. In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. J Nucl Med 2008;49:674-8
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Zelenetz AD, Press OW, Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol 2001;19:3918-28
   PubMed Web of Science ®Google Scholar
• Fisher RI, Kaminski MS, Wahl RL, Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol 2005;23:7565-73
   PubMed Web of Science ®Google Scholar
• Horning SJ, Younes A, Jain V, Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol 2005;23:712-9
   PubMed Web of Science ®Google Scholar
• Witzig TE, Flinn IW, Gordon LI, Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol 2002;20:3262-9
   PubMed Web of Science ®Google Scholar
• Gordon LI, Molina A, Witzig T, Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004;103:4429-31
   PubMed Web of Science ®Google Scholar
• Kaminski MS, Tuck M, Estes J, 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 2005;352:441-9
   PubMed Web of Science ®Google Scholar
• Press OW, Unger JM, Braziel RM, Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006;24:4143-9
   PubMed Web of Science ®Google Scholar
• Press OW, Czuczman MS, Horning SJ. Combination chemotherapy with monoclonal antibody therapy in treating patients with newly diagnosed non-Hodgkin's lymphoma. ClinicalTrials.gov NCT00006721. Available from: http://clinicaltrials.gov/ct2/show/NCT00006721?term=NCT00006721&rank=1 [Lat accessed 11 February 2011]
   Google Scholar
• Morschhauser F, Radford J, Van Hoof A, Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008;26:5156-64
   PubMed Web of Science ®Google Scholar
• Dorken B, Moldenhauer G, Pezzutto A, HD39 (B3), a B lineage-restricted antigen whose cell surface expression is limited to resting and activated human B lymphocytes. J Immunol 1986;136:4470-9
   PubMed Web of Science ®Google Scholar
• Engel P, Nojima Y, Rothstein D, The same epitope on CD22 of B lymphocytes mediates the adhesion of erythrocytes, T and B lymphocytes, neutrophils, and monocytes. J Immunol 1993;150:4719-32
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol 2003;21:3051-9
   PubMed Web of Science ®Google Scholar
• Leonard JP, Coleman M, Ketas JC, Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 2004;10:5327-34
   PubMed Web of Science ®Google Scholar
• Hernandez-Ilizaliturri F, Gada P, Repasky E, Czuczman M. Enhancement in anti-tumor activity of rituximab when combined with epratuzumab or apolizumab (Hu1D10) in a B-cell lymphoma severe combined deficiency (SCID) mouse model. ASH Annual Meeting Abstracts. Blood 2002;100:591
   Google Scholar
• Leonard JP, Coleman M, Matthews JC, Epratuzumab (anti-CD22) and rituximab (anti-CD20) combination immunotherapy for non-Hodgkin's lymphoma: preliminary response data. Proc Am Soc Clin Oncol 2002;21:1060
   Google Scholar
• Leonard JP, Coleman M, Ketas J, Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 2005;23:5044-51
   PubMed Web of Science ®Google Scholar
• Strauss SJ, Morschhauser F, Rech J, Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2006;24:3880-6
   PubMed Web of Science ®Google Scholar
• Leonard JP, Schuster SJ, Emmanouilides C, Durable complete responses from therapy with combined epratuzumab and rituximab: final results from an international multicenter, phase 2 study in recurrent, indolent, non-Hodgkin lymphoma. Cancer 2008;113:2714-23
   PubMed Web of Science ®Google Scholar
• Micallef IN, Maurer MJ, Nikcevich DA, Final results of NCCTG N0489: epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy (ER-CHOP) in patients with previously untreated diffuse large B-cell lymphoma. J Clin Oncol 2009;27(15S):8508
   Google Scholar
• Rosen PJ. Epratuzumab in treating patients with non-Hodgkin's lymphoma. ClinicalTrials.gov NCT00022685. Available from: http://clinicaltrials.gov/ct2/show/NCT00022685?term=NCT00022685&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Hernandez-Ilizaliturri FJ, Devineni S, Arora S, Targeting CD20 and CD22 with rituximab in combination with CMC-544 results in improved anti-tumor activity against non-Hodgkin's lymphoma (NHL) pre-clinical models. ASH Annual Meeting Abstracts. Blood 2005;106(11):1473
   PubMedGoogle Scholar
• Advani A, Coiffier B, Czuczman MS, Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a Phase I study. J Clin Oncol 2010;28:2085-93
   PubMed Web of Science ®Google Scholar
• Dang NH, Smith MR, Offner F, Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity including survival in patients with recurrent/refractory follicular or 'aggressive' lymphoma. ASH Annual Meeting Abstracts. Blood 2009;114(22):584
   Google Scholar
• Qu Z, Goldenberg DM, Cardillo TM, Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action. Blood 2008;111:2211-9
   PubMed Web of Science ®Google Scholar
• Rossi EA, Goldenberg DM, Cardillo TM, Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma. Blood 2009;113:6161-71
   PubMed Web of Science ®Google Scholar
• Stanglmaier M, Faltin M, Ruf P, Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 2008;123:1181-9
   PubMed Web of Science ®Google Scholar
• Buhmann R, Simoes B, Stanglmaier M, Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion. Bone Marrow Transplant 2009;43:383-97
   PubMed Web of Science ®Google Scholar
• Ely P. Antibody therapy in treating patients with refractory or relapsed non-Hodgkin's lymphoma or chronic lymphocytic leukemia. ClinicalTrials.gov NCT00014560. Available from: http://clinicaltrials.gov/ct2/show/NCT00014560?term=NCT00014560&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Brischwein K, Parr L, Pflanz S, Strictly target cell-dependent activation of T cells by bispecific single-chain antibody constructs of the BiTE class. J Immunother 2007;30:798-807
   PubMed Web of Science ®Google Scholar
• d'Argouges S, Wissing S, Brandl C, Combination of rituximab with blinatumomab (MT103/MEDI-538), a T cell-engaging CD19-/CD3-bispecific antibody, for highly efficient lysis of human B lymphoma cells. Leuk Res 2009;33:465-73
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 2008;321:974-7
   PubMed Web of Science ®Google Scholar
• Bargou RC, Kufer P, Goebeler M, Sustained response duration seen after treatment with single agent blinatumomab (MT103/MEDI-538) in the ongoing phase I study MT103- 104 in patients with relapsed NHL. ASH Annual Meeting Abstracts. Blood 2008;112(11):267
   Google Scholar
• Kostelny SA, Link BK, Tso JY, Humanization and characterization of the anti-HLA-DR antibody 1D10. Int J Cancer 2001;93:556-65
   PubMed Web of Science ®Google Scholar
• Stockmeyer B, Schiller M, Repp R, Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10 – a humanized human leucocyte antigen DR antibody. Br J Haematol 2002;118:959-67
   PubMed Web of Science ®Google Scholar
• Link B, Wang H, Byrd J, Phase I study of Hu1D10 monoclonal antibody in patients with B-cell lymphoma [abstract 1135]. Proc Am Soc Clin Oncol 2001;20:284a
   Google Scholar
• Brown KS, Levitt DJ, Shannon M, Link BK. Phase II trial of remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma. Clin Lymphoma 2001;2:188-90
   PubMedGoogle Scholar
• Dunleavy K, White T, Grant N, Phase 1 study of combination rituximab with apolizumab in relapsed/refractory B-cell lymphoma and chronic lymphocytic leukemia. J Clin Oncol 2005;23(16 Suppl):6607
   PubMedGoogle Scholar
• Geldart T, Illidge T. Anti-CD 40 monoclonal antibody. Leuk Lymphoma 2005;46:1105-13
   PubMed Web of Science ®Google Scholar
• O'Grady JT, Stewart S, Lowrey J, CD40 expression in Hodgkin's disease. Am J Pathol 1994;144:21-6
   PubMed Web of Science ®Google Scholar
• French RR, Chan HT, Tutt AL, Glennie MJ. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med 1999;5:548-53
   PubMed Web of Science ®Google Scholar
• Honeychurch J, Glennie MJ, Johnson PW, Illidge TM. Anti-CD40 monoclonal antibody therapy in combination with irradiation results in a CD8 T-cell-dependent immunity to B-cell lymphoma. Blood 2003;102:1449-57
   PubMed Web of Science ®Google Scholar
• Law CL, Gordon KA, Collier J, Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res 2005;65(18):8331-8
   PubMed Web of Science ®Google Scholar
• Advani R, Forero-Torres A, Furman RR, Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma. J Clin Oncol 2009;27:4371-7
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals. Study of HCD122 in adults with non-hodgkin's or hodgkin's lymphoma who have progressed after at least two prior therapies. ClinicalTrials.gov NCT00670592. Available from: http://clinicaltrials.gov/ct2/show/NCT00670592?term=NCT00670592&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Roche PA, Teletski CL, Stang E, Cell surface HLA-DR-invariant chain complexes are targeted to endosomes by rapid internalization. Proc Natl Acad Sci USA 1993;90:8581-5
   PubMed Web of Science ®Google Scholar
• Stein R, Mattes MJ, Cardillo TM, CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13(18 Pt 2):5556s-63s
   PubMed Web of Science ®Google Scholar
• Starlets D, Gore Y, Binsky I, Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 2006;107(12):4807-16
   PubMed Web of Science ®Google Scholar
• Stein R, Qu Z, Cardillo TM, Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies. Blood 2004;104(12):3705-11
   PubMed Web of Science ®Google Scholar
• Griffiths GL, Mattes MJ, Stein R, Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9:6567-71
   PubMed Web of Science ®Google Scholar
• Chang CH, Sapra P, Vanama SS, Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106:4308-14
   PubMed Web of Science ®Google Scholar
• Munro JM, Freedman AS, Aster JC, In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994;83:793-8
   PubMed Web of Science ®Google Scholar
• Vyth-Dreese FA, Boot H, Dellemijn TA, Localization in situ of costimulatory molecules and cytokines in B-cell non-Hodgkin's lymphoma. Immunology 1998;94:580-6
   PubMed Web of Science ®Google Scholar
• Suvas S, Singh V, Sahdev S, Distinct role of CD80 and CD86 in the regulation of the activation of B cell and B cell lymphoma. J Biol Chem 2002;277:7766-75
   PubMed Web of Science ®Google Scholar
• Gottlieb AB, Kang S, Linden KG, Evaluation of safety and clinical activity of multiple doses of the anti-CD80 monoclonal antibody, galiximab, in patients with moderate to severe plaque psoriasis. Clin Immunol 2004;111:28-37
   PubMed Web of Science ®Google Scholar
• Czuczman MS, Thall A, Witzig TE, Phase I/II study of galiximab, an anti-CD80 antibody, for relapsed or refractory follicular lymphoma. J Clin Oncol 2005;23:4390-8
   PubMed Web of Science ®Google Scholar
• Leonard JP, Friedberg JW, Younes A, A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol 2007;18:1216-23
   PubMed Web of Science ®Google Scholar
• Friedberg JW, Younes A, Fisher DC, Durable responses in patients treated with galiximab (Anti-CD80) in combination with rituximab for relapsed or refractory follicular lymphoma: long-term follow-up of a phase II clinical trial. ASH Annual Meeting Abstracts. Blood 2008;112(11):1004
   Google Scholar
• Czuczman MS, Johnson J, Jung S, Cheson B. A phase II trial of extended induction galiximab (anti-CD80 monoclonal antibody) plus rituximab in previously untreated follicular lymphoma: initial report of CALGB 50402 [abstract 43]. Ann Oncol 2008;19(Suppl 4):iv130
   Google Scholar
• Biogen Idec. A study of galiximab + rituximab versus rituximab + placebo in follicular non-Hodgkin's lymphoma (NHL). ClinicalTrials.gov NCT00363636. Available from: http://clinicaltrials.gov/ct2/show/NCT00363636?term=NCT00363636&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Smith SM, Bartlett NL. Galiximab in treating patients with relapsed or refractory Hodgkin's lymphoma. ClinicalTrials.gov NCT00516217: Available from: http://clinicaltrials.gov/ct2/show/NCT00516217?term=NCT00516217&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Clodi K, Younes A. Reed-Sternberg cells and the TNF family of receptors/ligands. Leuk Lymphoma 1997;27:195-205
   PubMed Web of Science ®Google Scholar
• Wahl AF, Klussman K, Thompson JD, The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res 2002;62:3736-42
   PubMed Web of Science ®Google Scholar
• Forero-Torres A, Leonard JP, Younes A, A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. Br J Haematol 2009;146:171-9
   PubMed Web of Science ®Google Scholar
• Blum KA, Jung SH, Johnson JL, Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcgammaRIIIa-158 V/F polymorphism. Ann Oncol 2010;21:2246-54
   PubMed Web of Science ®Google Scholar
• Duvic M, Reddy SA, Pinter-Brown L, A Phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders. Clin Cancer Res 2009;15:6217-24
   PubMed Web of Science ®Google Scholar
• Younes A, Zalevsky J, Blum KA, Evaluation of the pharmacokinetics, immunogenicity, and safety of XmAb(R)2513 in the ongoing study XmAb2513-01: a phase 1 study of every other week XmAb2513 to evaluate the safety, tolerability, and pharmacokinetics in patients with hodgkin lymphoma or anaplastic large cell lymphoma. ASH Annual Meeting Abstracts. Blood 2008;112(11):5012
   Google Scholar
• Okeley NM, Alley SC, Cerveny CG, Specific tumor targeting and potent bystander killing with SGN-35, an anti-CD30 antibody drug conjugate. ASH Annual Meeting Abstracts. Blood 2006;108(11):231
   Google Scholar
• Younes A, Forero-Torres A, Bartlett NL, Multiple complete responses in a Phase 1 dose-escalation study of the antibody-drug conjugate SGN-35 in patients with relapsed or refractory CD30-positive lymphomas. ASH Annual Meeting Abstracts. Blood 2008;112(11):1006
   Google Scholar
• Fanale M, Bartlett NL, Forero-Torres A, The antibody-drug conjugate brentuximab vedotin (SGN-35) induced multiple objective responses in patients with relapsed or refractory CD30-positive lymphomas in a phase 1 weekly dosing study. ASH Annual Meeting Abstracts. Blood 2009;114(22):2731
   Google Scholar
• Sievers E. A pivotal open-label trial of SGN-35 for Hodgkin lymphoma. ClinicalTrials.gov NCT00848926. Available from: http://clinicaltrials.gov/ct2/show/NCT00848926?term=NCT00848926&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Kennedy D. A phase 2 open label trial of SGN-35 for systemic anaplastic large cell lymphoma. ClinicalTrials.gov NCT00866047. Available from: http://clinicaltrials.gov/ct2/show/NCT00866047?term=NCT00866047&rank=1 [Last accessed 11 February 2011]
   Google Scholar
• Skov L, Kragballe K, Zachariae C, HuMax-CD4: a fully human monoclonal anti-CD4 antibody for the treatment of psoriasis vulgaris. Arch Dermatol 2003;139:1433-9
   PubMed Web of Science ®Google Scholar
• Springer TA. Adhesion receptors of the immune system. Nature 1990;346:425-34
   PubMed Web of Science ®Google Scholar
• Rider DA, Havenith CE, de Ridder R, A human CD4 monoclonal antibody for the treatment of T-cell lymphoma combines inhibition of T-cell signaling by a dual mechanism with potent Fc-dependent effector activity. Cancer Res 2007;67:9945-53
   PubMed Web of Science ®Google Scholar
• Kim YH, Duvic M, Obitz E, Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109:4655-62
   PubMed Web of Science ®Google Scholar
• d'Amore F, Radford J, Relander T, Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol 2010;150:565-73
   PubMed Web of Science ®Google Scholar
• Duvic M, Kim Y, Korman NJ, Zanolimumab, a fully human monoclonal antibody: early results of an ongoing clinical trial in patients with CD4+ mycosis fungoides (MF) type CTCL (Stage IB-IVB) who are refractory or intolerant to targretin and one other standard therapy. ASH Annual Meeting Abstracts. Blood 2006;108(11):2731
   Google Scholar
• Taskinen M, Karjalainen-Lindsberg ML, Nyman H, A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone. Clin Cancer Res 2007;13:5784-9
   PubMed Web of Science ®Google Scholar
• Canioni D, Salles G, Mounier N, High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial. J Clin Oncol 2008;26:440-6
   PubMed Web of Science ®Google Scholar
• Ashraf SQ, Umana P, Mossner E, Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis. Br J Cancer 2009;101:1758-68
   PubMedGoogle Scholar
• Richards JO, Karki S, Lazar GA, Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol Cancer Ther 2008;7:2517-27
   PubMed Web of Science ®Google Scholar
• Illidge TM. Radioimmunotherapy of lymphoma: a treatment approach ahead of its time or past its sell-by date? J Clin Oncol 2010;28:2944-6
   PubMed Web of Science ®Google Scholar